BrainStorm to Present at Precision Medicine World Conference 2018 Silicon Valley on January 22

HACKENSACK, N.J. and PETACH TIKVA, Israel, Jan. 16, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Chaim Lebovits, President & CEO, and Dr. Ralph Kern, COO & CMO, will be presenting at Precision Medicine World Conference (PMWC) 2018 Silicon Valley which will take place January 22-24 in Mountain View, California.

Presentation Details:

Session:                                  Emerging Therapeutics Showcase
Time:                                       10:45 a.m. PT, January 22
Location:                                 Computer History Museum, 1401 N Shoreline Blvd
                                                Mountain View, CA 94043

Brainstorm will participate in the Emerging Therapeutics Showcase session which will feature selected companies in the CRISPR, cell and gene therapy fields.

About Precision Medicine World Conference (PMWC)
The Precision Medicine World Conference (PMWC), formerly known as the Personalized Medicine World Conference, is an independent and established conference series considered to be the preeminent precision medicine conference that attracts recognized leaders, top global researchers and medical professionals, and innovators across healthcare and biotechnology sectors to showcase practical content that helps close the knowledge gap between different sectors, thereby catalyzing cross-functional fertilization and collaboration. Since 2009, recognized as a vital cornerstone for all constituents of the health care and biotechnology community, PMWC provides an exceptional forum for the exchange of information about the latest advances in technology, in clinical implementation, research, and in all aspects related to the regulatory and reimbursement sectors.

About NurOwn®
NurOwn® utilizes a patient's own cells which have been engineered outside the body, to produce and secrete factors known to promote neuronal survival. NurOwn® has the potential to be the first ALS treatment to improve patient functioning as a regenerative medicine. Regenerative medicine solutions are desperately needed in the field of neurodegenerative diseases as current therapies have limited efficacy, only slow progression and do not maintain or restore function. NurOwn® is currently being tested in a multi-site Phase 3 clinical trial in the U.S. and, if successful, the results from this trial will submitted to the FDA and other regulatory authorities around the world with the goal of obtaining marketing approval. BrainStorm has completed two single arm clinical trials which established the safety profile of NurOwn® and provided indications of a treatment benefit. Additionally, the company has completed a double-blind, placebo-controlled Phase 2 study at three prestigious academic medical centers in the US.  In this study, clinically meaningful changes in functioning were observed in patients receiving NurOwn®.

About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to approximately 75 patients with ALS in clinical trials conducted in the United States and Israel.  In a randomized, double-blind, placebo-controlled clinical trial conducted in the U.S., a clinically meaningful benefit was demonstrated by a higher response to NurOwn® compared with placebo. For more information, visit the company's website at www.brainstormcell.com.

Contacts

Corporate:
Uri Yablonka
Chief Business Officer
BrainStorm Cell Therapeutics Inc.
Phone: 646-666-3188  
uri@brainstorm-cell.com

Investors:
Michael Rice
LifeSci Advisors LLC
Phone: 646-597-6979 
mrice@lifesciadvisors.com

Media:
Matt Middleman, M.D.
LifeSci Public Relations, LLC
Phone: 646-627-8384 
matt@lifescipublicrelations.com

View original content with multimedia:http://www.prnewswire.com/news-releases/brainstorm-to-present-at-precision-medicine-world-conference-2018-silicon-valley-on-january-22-300583003.html

SOURCE BrainStorm Cell Therapeutics Inc.